Cargando…

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

BACKGROUND: After neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer, high pathologically complete response (pCR) rates are being achieved especially in patients with squamous cell carcinoma (SCC). An active surveillance strategy has been proposed for SCC patients with clinically complete re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaobin, Eyck, Ben M., Yang, Yang, Liu, Jun, Chao, Yin-Kai, Hou, Ming-Mo, Hung, Tsung-Min, Pang, Qingsong, Yu, Zhen-Tao, Jiang, Hongjing, Law, Simon, Wong, Ian, Lam, Ka-On, van der Wilk, Berend J., van der Gaast, Ate, Spaander, Manon C. W., Valkema, Roelf, Lagarde, Sjoerd M., Wijnhoven, Bas P. L., van Lanschot, J. Jan B., Li, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060643/ https://www.ncbi.nlm.nih.gov/pubmed/32143580 http://dx.doi.org/10.1186/s12885-020-6669-y

Ejemplares similares

Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial
por: van der Zijden, Charlène J., et al.
Publicado: (2022)

A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2
por: van der Zijden, Charlène J., et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses
por: Wijnhoven, Bas P. L., et al.
Publicado: (2009)

Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer
por: Eyck, Ben M., et al.
Publicado: (2021)

Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS)
por: Toxopeus, Eelke, et al.
Publicado: (2018)

Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon
por: Valkema, Maria J, et al.
Publicado: (2023)

Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy
por: van der Wilk, Berend J., et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
por: Noordman, Bo Jan, et al.
Publicado: (2018)

The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cells
por: Valkema, Maria J, et al.
Publicado: (2023)

Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer
por: de Jongh, M, et al.
Publicado: (2021)

Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer
por: Nederlof, Nina, et al.
Publicado: (2016)

Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison
por: Eyck, Ben M, et al.
Publicado: (2022)

Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer
por: Eyck, Ben M, et al.
Publicado: (2022)

External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
por: Valkema, Maria J., et al.
Publicado: (2023)

Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial
por: van der Wilk, B. J., et al.
Publicado: (2020)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
por: Valkema, M. J., et al.
Publicado: (2022)

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
por: Noordman, B. J., et al.
Publicado: (2019)

Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol
por: Noordman, Bo Jan, et al.
Publicado: (2015)

Delay in Diagnostic Workup and Treatment of Esophageal Cancer
por: Grotenhuis, Brechtje A., et al.
Publicado: (2009)

Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial
por: Boonstra, Jurjen J, et al.
Publicado: (2011)

Author response to: Comment on: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Author response to: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: Results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Author response to: Comment on: Outcomes after totally minimally invasive versus hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
por: van der Wilk, Berend J, et al.
Publicado: (2022)

Early onset esophageal adenocarcinoma: a distinct molecular entity?
por: van Nistelrooij, Anna M.J., et al.
Publicado: (2016)

Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction
por: Faber, Joyce, et al.
Publicado: (2015)

Esophageal cancer patients’ need for information and support in making a treatment decision between standard surgery and active surveillance
por: Hermus, Merel, et al.
Publicado: (2023)

Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2017)

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, Germany, France, Netherlands and Switzerland
por: Putora, Paul Martin, et al.
Publicado: (2015)

Clinical impact of routine response assessment after preoperative chemotherapy in patients with gastric cancer
por: van Hootegem, Sander J M, et al.
Publicado: (2023)

Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma
por: Ten Kate, Fiebo J.C., et al.
Publicado: (2017)

Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis
por: Spoor, Jonathan, et al.
Publicado: (2021)

Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma
por: van Nistelrooij, Anna M. J., et al.
Publicado: (2015)

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
por: van Heijl, M, et al.
Publicado: (2008)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

15-Year outcome after normal exercise (99m)Tc-sestamibi myocardial perfusion imaging: What is the duration of low risk after a normal scan?
por: Schinkel, Arend F. L., et al.
Publicado: (2012)

Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature
por: Collée, G. E., et al.
Publicado: (2020)

Destiempos del sino
por: Cruz, Toribio
Publicado: (2001)

Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma
por: Suzuki, Lucia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g49jrb4h50uhfol7h8p9s7je8s